What is the exact timeline of apotex's ruxolitinib application process?

When did Apotex file for ruxolitinib approval?

Apotex, a Canadian pharmaceutical company, filed for approval to market a generic version of the cancer medication ruxolitinib in the United States [1].

What is the status of Apotex's ruxolitinib application?

According to the FDA, the review of Apotex's application for a generic version of ruxolitinib was put on hold in March 2022, due to a patent challenge [2].

Which patent is the focus of the challenge?

The patent challenge in question is related to the JAK1/JAK2/ TYK2 inhibitor patent held by Incyte Corporation, the manufacturer of Jakafi, the branded version of ruxolitinib [3] DrugPatentWatch.com.

Is there a deadline for the resolution of this patent challenge?

The patent challenge, as well as the subsequent review of Apotex's application, is pending, and a specific timeline for its resolution has not been publicly disclosed.

What is the impact of this patent challenge on Apotex's application?

The patent challenge may affect the timeline for Apotex's application, potentially delaying its approval. However, the extent of the impact and the specific outcome of the patent challenge are currently unknown.

Sources

[1] FDA, Apotex Inc. - NDA 213-445

[2] Apotex - US FDA Approval Status

[3] Incyte Corporation. - Patent JP2019-510161

References

1. DrugPatentWatch.com (2023). JP2020-509161. Retrieved from DrugPatentWatch.com